Los Angeles Capital Management LLC Has $5.01 Million Position in Encompass Health Co. (NYSE:EHC)

Los Angeles Capital Management LLC grew its holdings in shares of Encompass Health Co. (NYSE:EHC) by 7.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,213 shares of the company’s stock after purchasing an additional 3,923 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Encompass Health were worth $5,007,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. International Assets Investment Management LLC acquired a new stake in Encompass Health in the 3rd quarter valued at approximately $4,241,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Encompass Health by 1.5% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 13,151 shares of the company’s stock valued at $1,271,000 after buying an additional 199 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Encompass Health by 6.5% in the third quarter. State of Alaska Department of Revenue now owns 12,866 shares of the company’s stock valued at $1,242,000 after buying an additional 790 shares during the period. First Trust Direct Indexing L.P. raised its holdings in Encompass Health by 11.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 2,851 shares of the company’s stock valued at $276,000 after acquiring an additional 304 shares in the last quarter. Finally, US Bancorp DE raised its stake in shares of Encompass Health by 18.7% in the third quarter. US Bancorp DE now owns 1,259 shares of the company’s stock valued at $122,000 after purchasing an additional 198 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Price Performance

Shares of EHC stock opened at $100.27 on Friday. The firm has a market cap of $10.10 billion, a price-to-earnings ratio of 22.48, a PEG ratio of 2.31 and a beta of 0.90. Encompass Health Co. has a 12 month low of $73.68 and a 12 month high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock has a 50-day moving average price of $96.31 and a 200 day moving average price of $96.20.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Research analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 17th. Investors of record on Tuesday, April 1st will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date is Tuesday, April 1st. Encompass Health’s dividend payout ratio is currently 15.25%.

Insider Activity

In other news, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on EHC. William Blair reissued an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. KeyCorp increased their price target on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Barclays lifted their price objective on Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. Finally, StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, February 15th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Encompass Health has a consensus rating of “Buy” and an average price target of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.